NCT05541315View on ClinicalTrials.gov

A Single Ascending Dose Study of JNJ-88260237 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

September 14, 2022

Primary Completion Date

May 9, 2023

Study Completion Date

May 9, 2023

Conditions

Healthy

Interventions

DRUG

JNJ-88260237

JNJ-88260237 will be administered orally.

DRUG

Placebo

Matching placebo will be administered orally.

Trial Locations (1)

68502

Celerion, Lincoln

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY